Ronald G. Gelbman Sells 5,440 Shares of Haemonetics Corporation (HAE) Stock

Haemonetics Corporation (NYSE:HAE) Director Ronald G. Gelbman sold 5,440 shares of the company’s stock in a transaction on Thursday, November 16th. The stock was sold at an average price of $56.69, for a total transaction of $308,393.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Shares of Haemonetics Corporation (HAE) opened at $57.99 on Friday. The company has a current ratio of 2.17, a quick ratio of 1.51 and a debt-to-equity ratio of 0.22. Haemonetics Corporation has a fifty-two week low of $36.44 and a fifty-two week high of $58.02. The stock has a market cap of $3,062.92, a PE ratio of 35.58, a price-to-earnings-growth ratio of 4.34 and a beta of 0.91.

Haemonetics Corporation (NYSE:HAE) last released its quarterly earnings results on Tuesday, November 7th. The medical instruments supplier reported $0.48 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.41 by $0.07. Haemonetics Corporation had a net margin of 0.50% and a return on equity of 11.16%. The company had revenue of $225.40 million during the quarter, compared to analysts’ expectations of $219.12 million. During the same period in the prior year, the company earned $0.38 earnings per share. The business’s quarterly revenue was up 2.3% compared to the same quarter last year. equities research analysts predict that Haemonetics Corporation will post 1.7 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This report was first reported by Transcript Daily and is the property of of Transcript Daily. If you are accessing this report on another publication, it was illegally stolen and republished in violation of US & international copyright and trademark legislation. The original version of this report can be accessed at https://transcriptdaily.com/2017/11/19/ronald-g-gelbman-sells-5440-shares-of-haemonetics-corporation-hae-stock.html.

Hedge funds have recently added to or reduced their stakes in the business. Arizona State Retirement System boosted its holdings in Haemonetics Corporation by 1.1% during the second quarter. Arizona State Retirement System now owns 27,397 shares of the medical instruments supplier’s stock valued at $1,082,000 after acquiring an additional 300 shares during the period. Aperio Group LLC raised its position in Haemonetics Corporation by 15.0% in the second quarter. Aperio Group LLC now owns 10,695 shares of the medical instruments supplier’s stock worth $422,000 after purchasing an additional 1,393 shares in the last quarter. Russell Investments Group Ltd. raised its position in Haemonetics Corporation by 12.2% in the second quarter. Russell Investments Group Ltd. now owns 23,503 shares of the medical instruments supplier’s stock worth $928,000 after purchasing an additional 2,553 shares in the last quarter. Kirr Marbach & Co. LLC IN raised its position in Haemonetics Corporation by 56.3% in the second quarter. Kirr Marbach & Co. LLC IN now owns 11,300 shares of the medical instruments supplier’s stock worth $446,000 after purchasing an additional 4,070 shares in the last quarter. Finally, Louisiana State Employees Retirement System raised its position in Haemonetics Corporation by 0.9% in the second quarter. Louisiana State Employees Retirement System now owns 21,400 shares of the medical instruments supplier’s stock worth $845,000 after purchasing an additional 200 shares in the last quarter.

A number of brokerages recently issued reports on HAE. Zacks Investment Research cut shares of Haemonetics Corporation from a “buy” rating to a “hold” rating in a report on Tuesday, August 29th. BidaskClub upgraded shares of Haemonetics Corporation from a “strong sell” rating to a “sell” rating in a report on Tuesday, August 8th. Morgan Stanley reiterated an “equal weight” rating and issued a $43.00 price objective (up from $38.00) on shares of Haemonetics Corporation in a report on Friday, October 6th. Barrington Research upgraded shares of Haemonetics Corporation from a “market perform” rating to an “outperform” rating and set a $48.00 price objective for the company in a report on Tuesday, August 8th. Finally, Craig Hallum reiterated a “hold” rating and issued a $50.00 price objective (up from $40.00) on shares of Haemonetics Corporation in a report on Wednesday, November 8th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $53.33.

Haemonetics Corporation Company Profile

Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.

Receive News & Ratings for Haemonetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply